See the rest here:
Starton Therapeutics Announces Successful Feasibility Demonstration of STAR-LLD Using BD Evolve™ On-Body Injector
Related Post
- Kineta, Inc Transitioning from Nasdaq to OTC Markets - September 20th, 2024
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - September 20th, 2024
- Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference - September 20th, 2024
- Financière de Tubize - Transparency notification - September 20th, 2024
- Inbiome, developing a new PCR technology capable of simultaneous identification of hundreds of bacterial pathogens in a single test, welcomes... - September 20th, 2024
- Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination - September 20th, 2024
- 213,285 Orion Corporation A shares converted into B shares - September 20th, 2024
- DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple... - September 20th, 2024
- Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive... - September 20th, 2024
- Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old - September 20th, 2024
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union - September 20th, 2024
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old - September 20th, 2024
- Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed - September 20th, 2024
- Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - September 20th, 2024
- Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with... - September 20th, 2024
- Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - September 20th, 2024
- T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union - September 20th, 2024
- Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs - September 20th, 2024
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - September 20th, 2024
- Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - September 20th, 2024
- Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World... - September 18th, 2024
- New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma - September 18th, 2024
- Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug - September 18th, 2024
- Procaps Issues Shareholder Letter Update - September 18th, 2024
- Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - September 18th, 2024
- Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - September 18th, 2024
- Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing - September 18th, 2024
- Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024 - September 18th, 2024
- Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors - September 18th, 2024
- Revolo Announces New Preclinical Data Further Validating Atopic Dermatitis as a Target Indication for ‘1104 - September 18th, 2024
- BioCardia Regains Full Compliance with Nasdaq Listing Requirements - September 18th, 2024
- GRI Bio Participates in Virtual Investor KOL Connect Segment - September 18th, 2024
- Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - September 18th, 2024
- Business update - opdatering på identitetsændring: - September 18th, 2024
- Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products... - September 18th, 2024
- Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data... - September 18th, 2024
- Kaida BioPharma Launches Social Media Channels - September 18th, 2024
- SoCalBio’s 26th Annual Two-Day Investor Partnership Conference hosted at the Hyatt Regency Newport Beach for the Medical Device and Biotechnology... - September 18th, 2024
- Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal... - September 18th, 2024
- Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT... - September 16th, 2024
- Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early... - September 16th, 2024
- Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer... - September 16th, 2024
- Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting... - September 16th, 2024
- Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - September 16th, 2024
- Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected - September 16th, 2024
- ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences - September 16th, 2024
- PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 - September 16th, 2024
- Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic... - September 16th, 2024
- Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01 - September 16th, 2024
- Bio-Path Holdings Announces Publication in Biomedicines - September 16th, 2024
- BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on... - September 16th, 2024
- Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health - September 16th, 2024
- Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo - September 16th, 2024
- InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System - September 16th, 2024
- Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid... - September 16th, 2024
- BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - September 16th, 2024
- Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies - September 16th, 2024
- Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile... - September 16th, 2024
- Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer - September 16th, 2024
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial... - September 14th, 2024
- Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th - September 14th, 2024
- Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - September 14th, 2024
- Virbac 2024 half-year results - September 14th, 2024
- Virbac : the board of directors announces a capital reduction through cancellation of treasury shares - September 14th, 2024
- Virbac: Information on the departure of Sébastien Huron - September 14th, 2024
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - September 14th, 2024
- Virbac : Half-yearly financial report 2024 - September 14th, 2024
- Virbac : Public release of the Half-Year Financial Report at 30 June 2024. - September 14th, 2024
- Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. - September 14th, 2024
- Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq - September 14th, 2024
- iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of... - September 14th, 2024
- Company Statement on FDA Advisory Committee Meeting - September 14th, 2024
- Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing,... - September 14th, 2024
- IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer - September 14th, 2024
- RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated... - September 14th, 2024
- Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - September 14th, 2024
- Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer - September 14th, 2024
- Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 - September 14th, 2024
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations... - September 14th, 2024
- PacBio Announces the HiFi Solves Sub-fertility Consortium in Asia Pacific - September 12th, 2024
Recent Comments